Navigation Links
QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
Date:10/12/2010

> QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

Under the terms of the agreements, QIAGEN will receive kits for a PCR-based molecular assay for HIV-1 viral load testing in the U.S. and Canada which will be commercialized under QIAGEN's brand. This test will enable healthcare professionals to measure the viral load of HIV infections in patients. It is expected that the new HIV-1 test will be available by 2012, thereby adding to QIAGEN's pipeline of U.S. regulatory submissions which is expected to also include a quantitative HBV (Hepatitis B) test. In addition, Abbott will provide a quantitative HCV (Hepatitis C) test which will be optimized and labeled for use on QIAGEN's QIAsymphony RGQ instrument and marketed under the Abbott brand in the U.S. and Canada. Subject to regulatory approval, this test may be available by the end of 2012.

QIAGEN will supply Abbott with certain key products required for a PCR-based HPV (human papillomavirus) test in the U.S. and Canada. This test will run on Abbott's m2000 lab automation system which features throughput up to 96 samples per run. QIAGEN itself will continue to address the HPV screening market with its prevention platform QIAensemble which is designed to process up to 2,000 samples per shift. Technologies which are the basis of QIAGEN's current and next-generation HPV screening assays are not subject to the transaction.

Tests for HIV and HCV are currently among the most widely used commercial applications in molecular diagnostics, with U.S. markets estimated to be in the range of US$ 180 and 140 million in annual sales, respectively. Laboratories with molecular diagnostic capabilities usually include these frequently performed assays in their testing me
'/>"/>

SOURCE QIAGEN
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
2. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
3. QIAGEN Acquires Exclusive Licence for Key PI3K gene
4. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
6. Plexus Awarded Development Contract With QIAGEN
7. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
8. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
9. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
10. SciQuest Announces Strategic Alliance with QIAGEN
11. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Thera, Inc.,announced today that the United States Patent ... "Protein-fragment Complementation,Assays (PCA) in whole animals: applications to ... gene therapy." This is the,twelfth patent issued for ... a method for detecting protein-protein,interactions in living cells ...
... Dec. 12 Genaera,Corporation (Nasdaq: GENR ) today ... Genaera, is scheduled to present at the 2007,RBC Capital ... Capital Markets, panel discussion of diabetes and obesity, entitled,"The ... place in,New York on Thursday, December 13 at 10:00 ...
... (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ) of Albuquerque, ... (New Mexico Tech at, http://www.nmt.edu ) reached an ... development of specialized image recognition technology as,part of ... early,detection of lung cancer., New Mexico Tech, ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2Biomoda Announces Collaborative Agreement With New Mexico Tech 2
(Date:4/17/2014)... eight hundred births, Down syndrome - or trisomy 21 ... disability. It results from a chromosomal abnormality where cells ... 21 (1% of the human genome). A study conducted ... of Genetic Medicine and Development at the University of ... , shed light on how the extra chromosome 21 ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... implicated in many serious conditions such as heart disease, ... for drug therapies. Unfortunately, there is still much scientists ... provides fresh and unexpected insight into the structure of ... β-subunit molecules - which are responsible for ,fine-tuning, the ... the most recent edition of the Journal of ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... , ,Mathematical models continue to play a major ... and control of malaria, a life-threatening parasitic disease ... Although existing models have advanced our understanding of ... new challenges., The National Institute for Mathematical and ...
... JOLLA, CA January 18, 2011 Using chemical compounds ... clever application of ultraviolet light, a Scripps Research Institute team ... to test for biomedical potential. Already, one of the compounds ... and fighting inflammation. With the report of their ...
... how the hormones progesterone and estrogen interact to increase ... a novel finding that may explain why postmenopausal women ... at increased risk of breast cancer. The discovery ... the increased production of the protein amphiregulin, which binds ...
Cached Biology News:Malaria modeling and control focus of workshop 2Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3Researchers unlock how progesterone increases breast cancer risk 2